ClinicalTrials.gg
CompletedNCT00540124Updated Nov 25, 2010Results posted

Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men

A Phase 2 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 5 sites in Korea, Republic of. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2010-11-25.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
17th of 26
151 · median 258
Started
2007
the only one that year
Phase 2
4 of 26
none open now
Registered
3rd of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 17th largest by enrollment, is the only one that started in 2007, is one of 4 in phase 2, and was the 3rd registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The primary purpose of this clinical trial is to evaluate the change in the International Prostate Symptom Score (IPSS) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg once a day dosing and placebo once a day dosing for 12 weeks of treatment.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Benign Prostatic Hyperplasia - Lower Urinary Tract Symptoms (BPH-LUTS) for at least 6 months prior to Visit 1.
  • Agree not to use any other approved or experimental treatments for erectile dysfunction or BPH-LUTS during the study.
  • Have not taken Finasteride therapy for at least 3 months prior to Visit 2.
  • Have not taken Dutasteride therapy for at least 6 months prior to Visit 2.
  • Have an International Prostate Symptom Score (IPSS) total score greater than or equal to 13 at Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Prostate Specific Antigen (PSA) greater than 10.0 nanograms per milliliter (ng/mL) at Visit 1.
  • Bladder Post Void Residual (PVR) greater than or equal to 300 mL by ultrasound at Visit 1.
  • History of pelvic surgery, prostatectomy, radiotherapy, penile implant surgery, lower urinary tract or trauma.
  • Urinary tract infection or inflammation or current antibiotic therapy for urinary tract infection at Visit 1.
  • Glycosylated () greater than 9% at Visit 1.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Tadalafil

    Drug: Tadalafil

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Tamsulosin

    Drug: Tamsulosin

Interventions

  • 5 mg once a day

    Also known as: LY450190, Cialis

  • DrugPlacebo

    once a day

  • 0.2 mg once a day

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score

    The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline to 4 Week and 8 Week Endpoints in International Prostate Symptom Score (IPSS) Total Score

    The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: baseline, 4 and 8 weeks

  2. Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Irritative Subscore

    The IPSS storage (irritative) subscore is defined as sum of scores for Questions 2, 4, and 7 of the IPSS. If scores for any of these questions are missing for a visit, the IPSS storage subscore will be reported as missing for that visit. Subscore totals range from 0 to 15; higher scores are indicative of greater irritation.

    Time frame: baseline, 4, 8, and 12 weeks

  3. Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Obstructive Subscore

    The IPSS voiding (obstructive) subscore is defined as sum of scores for Questions 1, 3, 5, and 6 of the IPSS. If scores for any of these questions are missing for a visit, the IPSS voiding subscore will be reported as missing for that visit. Subscore totals range from 0 to 20; higher scores are indicative of greater obstruction.

    Time frame: baseline, 4, 8, and 12 weeks

  4. Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Nocturia Subscore

    IPSS Question 7 is used to assess the frequency of nocturia. Scores range from 0 (low frequency of nocturia) to 5 (high frequency of nocturia).

    Time frame: baseline, 4, 8, and 12 weeks

  5. Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BPH-II)

    The BPH-BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range of 0 to 13; higher scores represent increased perceived impact of BPH-LUTS on overall health. If scores for any component question were missing for a visit, BPH-BII was reported as missing for that visit.

    Time frame: baseline, 12 weeks

  6. Patient Global Impression of Improvement (PGI-I) Combined Categories - Frequencies

    A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). Scores were combined to provide number of participants who indicated they were "worse" (scores of 5, 6, or 7), "no change" (score of 4), or "better" (scores of 1, 2, or 3).

    Time frame: 12 weeks

  7. Clinician Global Impression of Improvement (CGI-I) Combined Categories - Frequencies

    Measures clinician's perception of patient improvement of illness at the time of assessment compared with start of treatment. Scores range from 1 (very much better) to 7 (very much worse). Scores were combined to provide number of participants whose clinician indicated they were "worse" (scores of 5, 6, or 7), "no change" (score of 4), or "better" (scores of 1, 2, or 3).

    Time frame: 12 weeks

  8. Change From Baseline to 12 Week Endpoint in Total, Waking, and Sleeping Voids (Average Number Per Week) Based on Median as Reported in Patient Voiding Dribble Diary

    Patient-completed diary that measures daytime frequency (waking voids) and nocturia (sleeping voids). Average number of waking voids per week, average number of sleeping voids per week, and average number of total voids (sleeping+waking) per week are reported.

    Time frame: baseline, 12 weeks

  9. Change From Baseline to 12 Week Endpoint in Total Urinary Incontinence Episodes Per Week Based on Median as Reported in Patient Voiding Dribble Diary

    A patient-completed diary that measures urinary incontinence (UI) (leaks). Number of UI leaks per week are reported.

    Time frame: baseline, 12 weeks

  10. Change From Baseline to 12 Week Endpoint in Voids With Terminal Micturition Dribble and Post Micturition Dribble Per Week Based on Median as Reported by Patient Voiding Dribble Diary

    A patient-completed diary that measures terminal dribble (dribble in the end of urination) and post-micturition dribble (dribble after urination).

    Time frame: baseline, 12 weeks

  11. Change From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) and Mean Urine Flow Rate (Qmean)

    Qmax: defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using a standard calibrated flowmeter); and Qmean, defined as the mean urine flow rate (measured in mL/second using a standard calibrated flowmeter).

    Time frame: baseline, 12 weeks

  12. Change From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Voided Urine Volume (Vcomp)

    Vcomp, defined as the volume of voided urine (measured in milliliters \[mL\]).

    Time frame: baseline, 12 weeks

07

Results

Posted Jul 20, 2009

Participant flow

Participant flow — Overall Study
MilestonePlaceboTadalafilTamsulosin
Started515149
Completed474848
Not completed431
Withdrew: Adverse event021
Withdrew: Entry criteria not met200
Withdrew: Lack of efficacy100
Withdrew: Withdrawal by subject110

Outcome measures

PrimaryChange From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score

The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
baseline, 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score
units on a scalePlaceboTadalafilTamsulosin
Baseline17.3 ± 5.017.1 ± 5.417.7 ± 5.0
12 Week Change-4.2 ± 4.8-5.8 ± 4.6-5.6 ± 5.3
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.073 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.186 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
SecondaryChange From Baseline to 4 Week and 8 Week Endpoints in International Prostate Symptom Score (IPSS) Total Score

The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
baseline, 4 and 8 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4 Week and 8 Week Endpoints in International Prostate Symptom Score (IPSS) Total Score
units on a scalePlaceboTadalafilTamsulosin
4 Week Change (n=50, n=49, n=49)-2.8 ± 0.6-4.0 ± 0.6-4.0 ± 0.6
8 Week Change (n=47, n=50, n=48)-3.3 ± 0.7-4.8 ± 0.6-4.8 ± 0.7
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.155 (P-value for 4 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.155 (P-value for 4 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tadalafil · ANCOVA · p = 0.108 (P-value for 8 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.112 (P-value for 8 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
SecondaryChange From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Irritative Subscore

The IPSS storage (irritative) subscore is defined as sum of scores for Questions 2, 4, and 7 of the IPSS. If scores for any of these questions are missing for a visit, the IPSS storage subscore will be reported as missing for that visit. Subscore totals range from 0 to 15; higher scores are indicative of greater irritation.

Time frame:
baseline, 4, 8, and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Irritative Subscore
units on a scalePlaceboTadalafilTamsulosin
Baseline (n=50, n=50, n=49)6.7 ± 2.06.7 ± 2.76.5 ± 2.6
4 Week Change (n=50, n=49, n=49)-0.8 ± 2.1-1.4 ± 2.4-1.7 ± 2.1
8 Week Change (n=47, n=50, n=48)-0.9 ± 2.0-1.6 ± 2.5-1.9 ± 2.3
12 Week Change (n=47, n=48, n=48)-1.6 ± 2.1-2.2 ± 2.4-1.8 ± 2.7
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.137 (P-value for 4 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.009 (P-value for 4 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tadalafil · ANCOVA · p = 0.118 (P-value for 8 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.018 (P-value for 8 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tadalafil · ANCOVA · p = 0.207 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.581 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
SecondaryChange From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Obstructive Subscore

The IPSS voiding (obstructive) subscore is defined as sum of scores for Questions 1, 3, 5, and 6 of the IPSS. If scores for any of these questions are missing for a visit, the IPSS voiding subscore will be reported as missing for that visit. Subscore totals range from 0 to 20; higher scores are indicative of greater obstruction.

Time frame:
baseline, 4, 8, and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Obstructive Subscore
units on a scalePlaceboTadalafilTamsulosin
Baseline (n=50, n=50, n=49)10.6 ± 3.710.4 ± 3.811.2 ± 3.7
4 Week Change (n=50, n=49, n=49)-2.0 ± 4.0-2.6 ± 3.1-2.4 ± 3.1
8 Week Change (n=47, n=50, n=48)-2.3 ± 4.1-3.1 ± 3.1-3.1 ± 3.8
12 Week Change (n=47, n=48, n=48)-2.7 ± 3.6-3.6 ± 3.4-3.9 ± 3.6
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.306 (P-value for 4 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.762 (P-value for 4 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tadalafil · ANCOVA · p = 0.203 (P-value for 8 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.464 (P-value for 8 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tadalafil · ANCOVA · p = 0.169 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.243 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
SecondaryChange From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Nocturia Subscore

IPSS Question 7 is used to assess the frequency of nocturia. Scores range from 0 (low frequency of nocturia) to 5 (high frequency of nocturia).

Time frame:
baseline, 4, 8, and 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 4, 8, and 12 Week Endpoints in International Prostate Symptom Score (IPSS) - Nocturia Subscore
units on a scalePlaceboTadalafilTamsulosin
Baseline (n=50, n=50, n=49)2.0 ± 1.11.8 ± 1.01.7 ± 1.0
4 Week Change (n=50, n=49, n=49)-0.3 ± 0.9-0.4 ± 0.9-0.3 ± 1.0
8 Week Change (n=47, n=50, n=48)-0.4 ± 0.7-0.4 ± 1.0-0.4 ± 1.2
12 Week Change (n=47, n=48, n=48)-0.5 ± 0.9-0.5 ± 0.9-0.5 ± 1.1
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.206 (P-value for 4 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.457 (P-value for 4 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tadalafil · ANCOVA · p = 0.892 (P-value for 8 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.593 (P-value for 8 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tadalafil · ANCOVA · p = 0.887 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.762 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from ANCOVA with effects for treatment, prior alpha blocker use (yes/no), time (visit), baseline value, and time\*treatment interaction. Model used an unstructured covariance.)
SecondaryChange From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BPH-II)

The BPH-BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range of 0 to 13; higher scores represent increased perceived impact of BPH-LUTS on overall health. If scores for any component question were missing for a visit, BPH-BII was reported as missing for that visit.

Time frame:
baseline, 12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BPH-II)
units on a scalePlaceboTadalafilTamsulosin
Baseline6.2 ± 2.86.1 ± 2.96.2 ± 3.1
12 Week Change-2.0 ± 2.7-2.2 ± 2.9-1.7 ± 2.6
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.691 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.415 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
SecondaryPatient Global Impression of Improvement (PGI-I) Combined Categories - Frequencies

A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). Scores were combined to provide number of participants who indicated they were "worse" (scores of 5, 6, or 7), "no change" (score of 4), or "better" (scores of 1, 2, or 3).

Time frame:
12 weeks
Reported as:
Number · participants
Patient Global Impression of Improvement (PGI-I) Combined Categories - Frequencies
participantsPlaceboTadalafilTamsulosin
Worse113
No Change1057
Better374338
Statistical analysis
  • Placebo vs Tadalafil · Cochran-Mantel-Haenszel · p = 0.176 (P-value based on Cochran-Mantel-Haenszel Test with modified ridit scores controlling for alpha block use (yes/no) and lower urinary tract symptom severity as stratification factors.)
  • Placebo vs Tamsulosin · Cochran-Mantel-Haenszel · p = 0.921 (P-value based on Cochran-Mantel-Haenszel Test with modified ridit scores controlling for alpha block use (yes/no) and lower urinary tract symptom severity as stratification factors.)
SecondaryClinician Global Impression of Improvement (CGI-I) Combined Categories - Frequencies

Measures clinician's perception of patient improvement of illness at the time of assessment compared with start of treatment. Scores range from 1 (very much better) to 7 (very much worse). Scores were combined to provide number of participants whose clinician indicated they were "worse" (scores of 5, 6, or 7), "no change" (score of 4), or "better" (scores of 1, 2, or 3).

Time frame:
12 weeks
Reported as:
Number · participants
Clinician Global Impression of Improvement (CGI-I) Combined Categories - Frequencies
participantsPlaceboTadalafilTamsulosin
Worse004
No Change584
Better434140
Statistical analysis
  • Placebo vs Tadalafil · Cochran-Mantel-Haenszel · p = 0.429 (P-value based on Cochran-Mantel-Haenszel Test with modified ridit scores controlling for alpha block use (yes/no) and lower urinary tract symptom severity as stratification factors.)
  • Placebo vs Tamsulosin · Cochran-Mantel-Haenszel · p = 0.304 (P-value based on Cochran-Mantel-Haenszel Test with modified ridit scores controlling for alpha block use (yes/no) and lower urinary tract symptom severity as stratification factors.)
SecondaryChange From Baseline to 12 Week Endpoint in Total, Waking, and Sleeping Voids (Average Number Per Week) Based on Median as Reported in Patient Voiding Dribble Diary

Patient-completed diary that measures daytime frequency (waking voids) and nocturia (sleeping voids). Average number of waking voids per week, average number of sleeping voids per week, and average number of total voids (sleeping+waking) per week are reported.

Time frame:
baseline, 12 weeks
Reported as:
Mean · average number per week
Change From Baseline to 12 Week Endpoint in Total, Waking, and Sleeping Voids (Average Number Per Week) Based on Median as Reported in Patient Voiding Dribble Diary
average number per weekPlaceboTadalafilTamsulosin
Baseline Waking Voids48.2 ± 11.246.9 ± 11.148.4 ± 16.9
12 Week Change Waking Voids-0.3 ± 8.7-2.1 ± 8.7-1.3 ± 7.6
Baseline Sleeping Voids10.3 ± 7.89.8 ± 6.77.9 ± 5.4
12 Week Change Sleeping Voids-1.3 ± 3.5-2.3 ± 3.8-1.4 ± 4.0
Baseline Total Voids58.6 ± 13.056.7 ± 13.356.3 ± 19.2
12 Week Change Total Voids-1.6 ± 9.2-4.4 ± 9.7-2.7 ± 8.9
Statistical analysis
  • Placebo vs Tadalafil · Wilcoxon Rank Sum · p = 0.254 (P-value for 12 Week Change Waking Voids. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tamsulosin · Wilcoxon Rank Sum · p = 0.359 (P-value for 12 Week Change Waking Voids. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tadalafil · Wilcoxon Rank Sum · p = 0.098 (P-value for 12 Week Change Sleeping Voids. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tamsulosin · Wilcoxon Rank Sum · p = 0.632 (P-value for 12 Week Change Sleeping Voids. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tadalafil · Wilcoxon Rank Sum · p = 0.102 (P-value for 12 Week Change Total Voids. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tamsulosin · Wilcoxon Rank Sum · p = 0.348 (P-value for 12 Week Change Total Voids. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
SecondaryChange From Baseline to 12 Week Endpoint in Total Urinary Incontinence Episodes Per Week Based on Median as Reported in Patient Voiding Dribble Diary

A patient-completed diary that measures urinary incontinence (UI) (leaks). Number of UI leaks per week are reported.

Time frame:
baseline, 12 weeks
Reported as:
Mean · average number per week
Change From Baseline to 12 Week Endpoint in Total Urinary Incontinence Episodes Per Week Based on Median as Reported in Patient Voiding Dribble Diary
average number per weekPlaceboTadalafilTamsulosin
Baseline0.8 ± 3.61.1 ± 5.41.6 ± 5.0
12 Week Change-0.3 ± 3.50.7 ± 2.5-0.3 ± 4.9
Statistical analysis
  • Placebo vs Tadalafil · Wilcoxon Rank Sum · p = 0.208 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tamsulosin · Wilcoxon Rank Sum · p = 0.985 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
SecondaryChange From Baseline to 12 Week Endpoint in Voids With Terminal Micturition Dribble and Post Micturition Dribble Per Week Based on Median as Reported by Patient Voiding Dribble Diary

A patient-completed diary that measures terminal dribble (dribble in the end of urination) and post-micturition dribble (dribble after urination).

Time frame:
baseline, 12 weeks
Reported as:
Mean · average number per week
Change From Baseline to 12 Week Endpoint in Voids With Terminal Micturition Dribble and Post Micturition Dribble Per Week Based on Median as Reported by Patient Voiding Dribble Diary
average number per weekPlaceboTadalafilTamsulosin
Baseline Terminal Micturation Dribble68.7 ± 35.869.8 ± 37.077.5 ± 29.9
12 Week Change Terminal Micturation Dribble-11.7 ± 36.91.6 ± 31.9-8.5 ± 33.1
Baseline Post Micturation Dribble14.3 ± 27.017.8 ± 29.825.5 ± 32.6
12 Week Change Post Micturation Dribble-0.8 ± 29.5-4.8 ± 27.4-7.6 ± 34.9
Statistical analysis
  • Placebo vs Tadalafil · Wilcoxon Rank Sum · p = 0.385 (P-value for 12 Week Change Terminal Micturation Dribble. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tamsulosin · Wilcoxon Rank Sum · p = 0.595 (P-value for 12 Week Change Terminal Micturation Dribble. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tadalafil · Wilcoxon Rank Sum · p = 0.704 (P-value for 12 Week Change Post Micturation Dribble. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
  • Placebo vs Tamsulosin · Wilcoxon Rank Sum · p = 0.439 (P-value for 12 Week Change Post Micturation Dribble. Change=Endpoint minus baseline. P-values for pairwise comparison of change difference based on Wilcoxon Rank Sum test.)
SecondaryChange From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) and Mean Urine Flow Rate (Qmean)

Qmax: defined as the peak urine flow rate (measured in milliliters per second \[mL/second\] using a standard calibrated flowmeter); and Qmean, defined as the mean urine flow rate (measured in mL/second using a standard calibrated flowmeter).

Time frame:
baseline, 12 weeks
Reported as:
Mean · milliliters per second
Change From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) and Mean Urine Flow Rate (Qmean)
milliliters per secondPlaceboTadalafilTamsulosin
Baseline Qmax10.5 ± 3.611.4 ± 3.211.7 ± 4.6
12 Week Change Qmax2.8 ± 5.62.4 ± 5.21.9 ± 4.8
Baseline Qmean5.7 ± 2.36.1 ± 2.16.2 ± 3.0
12 Week Change Qmean2.0 ± 3.11.5 ± 2.91.0 ± 3.4
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.838 (P-value for 12 Week Change Qmax. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.831 (P-value for 12 Week Change Qmax. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tadalafil · ANCOVA · p = 0.696 (P-value for 12 Week Change Qmean. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.257 (P-value for 12 Week Change Qmean. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
SecondaryChange From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Voided Urine Volume (Vcomp)

Vcomp, defined as the volume of voided urine (measured in milliliters \[mL\]).

Time frame:
baseline, 12 weeks
Reported as:
Mean · milliliters
Change From Baseline to 12 Week Endpoint in Uroflowmetry Parameters - Voided Urine Volume (Vcomp)
millilitersPlaceboTadalafilTamsulosin
Baseline220.0 ± 67.7233.2 ± 86.7236.6 ± 78.4
12 Week Change21.4 ± 128.919.7 ± 109.223.9 ± 89.3
Statistical analysis
  • Placebo vs Tadalafil · ANCOVA · p = 0.709 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)
  • Placebo vs Tamsulosin · ANCOVA · p = 0.494 (P-value for 12 Week Change. Change=Endpoint minus baseline. P-values are from an ANCOVA with effects for treatment, prior alpha blocker use (yes/no), and baseline value, and were not adjusted for multiple comparisons.)

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo———
Tadalafil———
Tamsulosin———
Most frequent serious events
Most frequent serious events
EventPlaceboTadalafilTamsulosin
Acute myocardial infarctionCardiac disorders0/510/511/49
Inguinal herniaGastrointestinal disorders0/510/511/49
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/511/510/49
Lung adenocarcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/511/510/49
Pleural effusionRespiratory, thoracic and mediastinal disorders0/511/510/49
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboTadalafilTamsulosin
NasopharyngitisInfections and infestations0/511/515/49
MyalgiaMusculoskeletal and connective tissue disorders0/512/511/49
DyspepsiaGastrointestinal disorders0/510/511/49
Epigastric discomfortGastrointestinal disorders0/510/511/49
Gastric ulcer haemorrhageGastrointestinal disorders0/510/511/49
Chest painGeneral disorders0/510/511/49
Intentional overdoseInjury, poisoning and procedural complications0/511/511/49
Skin lacerationInjury, poisoning and procedural complications0/510/511/49
HyperlipidaemiaMetabolism and nutrition disorders0/510/511/49
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/510/511/49

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboTadalafilTamsulosinTotal
Mean62.2 ± 6.861.2 ± 6.661.5 ± 6.461.6 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTadalafilTamsulosinTotal
Female0000
Male515149151
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTadalafilTamsulosinTotal
American Indian or Alaska Native0000
Asian515149151
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)PlaceboTadalafilTamsulosinTotal
Korea, Republic of515149151
Erectile Dysfunction (ED)
Erectile Dysfunction (ED)(participants)PlaceboTadalafilTamsulosinTotal
Yes36302490
No15212561
Duration of Erectile Dysfunction (ED)
Duration of Erectile Dysfunction (ED)(participants)PlaceboTadalafilTamsulosinTotal
<3 Months0101
3 Months to < 6 Months2316
6 Months to < 1 Year53513
1 Year or More29231870
Etiology of Erectile Dysfunction (ED)
Etiology of Erectile Dysfunction (ED)(participants)PlaceboTadalafilTamsulosinTotal
Psychogenic2002
Organic16101137
Mixed17151244
Unknown1517
Severity of Erectile Dysfunction (ED)
Severity of Erectile Dysfunction (ED)(participants)PlaceboTadalafilTamsulosinTotal
Mild17221352
Moderate145726
Severe53412

5 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jeon Ju-City, 561-712, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kwang Ju, 501-757, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyunggi-Do, 425-020, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pusan, 614-735, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 140-757, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2007
First posted
Oct 5, 2007
Start
Oct 2007
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Jul 20, 2009
Last update
Nov 25, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00540124
First posted
Oct 5, 2007
Start date
Oct 2007
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Jul 20, 2009
Last update
Nov 25, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion